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Abstract
Introduction: Several common alleles have been shown to be associated with breast and/or ovarian cancer risk for
BRCA1 and BRCA2 mutation carriers. Recent genome-wide association studies of breast cancer have identified eight
additional breast cancer susceptibility loci: rs1011970 (9p21, CDKN2A/B), rs10995190 (ZNF365), rs704010 (ZMIZ1),
rs2380205 (10p15), rs614367 (11q13), rs1292011 (12q24), rs10771399 (12p11 near PTHLH) and rs865686 (9q31.2).
Methods: To evaluate whether these single nucleotide polymorphisms (SNPs) are associated with breast cancer
risk for BRCA1 and BRCA2 carriers, we genotyped these SNPs in 12,599 BRCA1 and 7,132 BRCA2 mutation carriers
and analysed the associations with breast cancer risk within a retrospective likelihood framework.
Results: Only SNP rs10771399 near PTHLH was associated with breast cancer risk for BRCA1 mutation carriers (per-allele
hazard ratio (HR) = 0.87, 95% CI: 0.81 to 0.94, P-trend = 3 × 10-4). The association was restricted to mutations proven or
predicted to lead to absence of protein expression (HR = 0.82, 95% CI: 0.74 to 0.90, P-trend = 3.1 × 10-5, P-difference =
0.03). Four SNPs were associated with the risk of breast cancer for BRCA2 mutation carriers: rs10995190, P-trend = 0.015;
rs1011970, P-trend = 0.048; rs865686, 2df-P = 0.007; rs1292011 2df-P = 0.03. rs10771399 (PTHLH) was predominantly
associated with estrogen receptor (ER)-negative breast cancer for BRCA1 mutation carriers (HR = 0.81, 95% CI: 0.74 to
0.90, P-trend = 4 × 10-5) and there was marginal evidence of association with ER-negative breast cancer for BRCA2
mutation carriers (HR = 0.78, 95% CI: 0.62 to 1.00, P-trend = 0.049).
Conclusions: The present findings, in combination with previously identified modifiers of risk, will ultimately lead
to more accurate risk prediction and an improved understanding of the disease etiology in BRCA1 and BRCA2
mutation carriers.
Introduction
Pathogenic mutations in BRCA1 and BRCA2 confer high
risks of breast and ovarian cancers [1,2]. Several lines of
evidence suggest that these risks are modified by other
genetic or environmental factors that cluster in families.
Direct evidence for genetic modifiers of risk has been
provided through studies that investigated the associa-
tions between common breast and ovarian cancer sus-
ceptibility variants, identified through genome-wide
association studies (GWAS) or candidate gene studies in
the general population, and cancer risk for BRCA1 and
BRCA2 mutation carriers [3-8] and through GWAS in
BRCA1 and BRCA2 mutation carriers [9-11]. Six loci (at
TOX3, 2q35, 6q25.1, 19p13, CASP8 and wild-type copy
of BRCA1) are now known to be associated with breast
cancer risk for BRCA1 mutation carriers; a further 10
loci (at FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7,
5p12, 1p11.2, ZNF365 and RAD51) have been associated
with breast cancer risk for BRCA2 carriers. The associa-
tion patterns between these common variants and breast
cancer risk for BRCA1 and BRCA2 mutation carriers are
in general different, and mostly reflect differences in the
associations of these single-nucleotide polymorphism
(SNPs) with estrogen receptor (ER) status of breast can-
cer [12-14].
GWAS in the general population have recently identi-
fied eight additional breast cancer susceptibility loci
which have not been previously investigated in BRCA1
and BRCA2 mutation carriers. Turnbull et al. [15] iden-
tified five susceptibility loci on chromosomes 9
(rs1011970), 10 (rs2380205, rs10995190, rs704010) and
11 (rs614367) through a GWAS of breast cancer cases
with a family history of the disease and unrelated con-
trols. In a further follow-up of additional promising
associations from that GWAS, the Breast Cancer Asso-
ciation Consortium (BCAC) has identified two addi-
tional loci at 12p11 (rs10771399) and 12q24 (rs1292011)
which were associated with breast cancer risk in the
general population [16]. The estimated odds ratios (OR)
for ER-positive breast cancer for four of these SNPs
(rs1011970 near CDKN2A/CDKN2B at chromosome 9,
rs10995190 in ZNF365 at chromosome 10, rs614367 at
11q13 and rs1292011 at 12q24) were higher than the
OR estimates for ER-negative breast cancer. In contrast,
the OR estimates were similar for ER-positive and ER-
negative breast cancer for SNPs rs2380205 (near
ANKRD16 and FBXO18), rs704010 (upstream of
ZMIZ1) and rs10771399 near PTHLH. In a separate
GWAS that included mainly cases with two primary
breast cancers or a family history of the disease, SNP
rs865686 at 9q31.2 was found to be associated with risk
for breast cancer, OR = 0.89 (95% CI: 0.85 to 0.92), but
no estimates by ER status were reported [17].
The associations of these eight loci with breast cancer
risk for BRCA1 and BRCA2 mutation carriers are still
unknown. To evaluate these associations, we genotyped
the eight SNPs in BRCA1 and BRCA2 mutation carriers
participating in the Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA). We further investi-
gated the associations with the risks of developing ER-
positive and ER-negative breast cancer and the risk of
ovarian cancer.
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Materials and methods
Subjects
All carriers participated in clinical or research studies at
the host institutions which have been approved by local
ethics committees (list provided in Additional file 1
Table S1). Informed consent was obtained from all
study participants. Subjects were BRCA1 and BRCA2
mutation carriers recruited by 40 study centres in 28
countries through CIMBA (Additional file 1 Table 2).
The majority of carriers (97.58%) were recruited through
cancer genetics clinics offering genetic testing, and
enrolled into national or regional studies. Some carriers
were identified by population-based sampling of cases
(2.38%), and some by community recruitment (0.04%).
Eligibility to participate in CIMBA is restricted to female
carriers of pathogenic BRCA1 or BRCA2 mutations age
18 years old or older at recruitment. Information col-
lected included the year of birth; mutation description,
including nucleotide position and base change; self
reported ethnic ancestry, age at last follow-up; ages at
breast or ovarian cancer diagnoses; and age or date at
bilateral prophylactic mastectomy and oophorectomy.
Related individuals were identified through a unique
family identifier. Women were included in the analysis if
they carried mutations that were pathogenic according
to generally recognized criteria [18]. Further details on
CIMBA can be found elsewhere [19].
Women who carried pathogenic mutations in both
BRCA1 and BRCA2 were excluded from the current
analysis. The primary analysis was restricted to women
self-reported as “white of European ancestry”. The num-
ber of mutation carriers of non-white ancestry was too
small to allow separate analysis. We investigated possi-
ble overlap of carriers between studies by comparing the
year of birth, exact mutation description and the
reported ages, to identify potential duplicate individuals.
Where possible we also used other genotype data on
SNPs genotyped in the current round (at least 26 SNPs),
in previous genotyping rounds or as part of GWAS to
find hidden duplicates. When a potential duplicate was
identified, we contacted the relevant centres for further
information about these individuals, in a manner that
protected the identity of the individuals in question, in
order to determine precisely the extent of true overlap
in subjects and families appearing more than once in
the data set. Duplicate mutation carriers were included
only once in the analysis. When in doubt, and when
centres could not clarify a potential duplication, one of
the samples was excluded from the analysis.
Genotyping
DNA samples (in almost all cases, obtained from blood)
were genotyped using the iPLEX Mass Array platform at
four genotyping centres (Additional file 1 Table S2); the
iPLEX included 26 SNPs as part of a larger study. All
centres included at least 2% of the samples in duplicate,
no template controls in every plate, and a random mix-
ture of affected and unaffected carriers. Samples that
failed for ≥ 20% of all the SNPs typed (that is, five or
more) were excluded from the analysis. A study was
included in the analysis only if the call rate was over
95%, after samples that failed at multiple SNPs had been
excluded. For each study, genotypes for at least 98% of
the duplicate samples had to be concordant. To assess
the accuracy of genotyping across genotyping centres,
the four centres genotyped 95 DNA samples from a
standard test plate (Coriell Institute) for all SNPs. If the
genotyping was inconsistent for more than one sample
in the test plate, all the studies genotyped at the centre
were excluded from the analysis of that SNP. No SNPs
failed this criterion. The present study included eight
SNPs: rs1011970 (9p21, near CDKN2A/B), rs10995190
(10q21, near ZNF365), rs704010 (10q22, near ZMIZ1),
rs2380205 (10p15), rs614367 (11q13), rs1292011
(12q24), rs10771399 (12p11 near PTHLH) and rs865686
(9q31.2). Based on the quality control criteria, 4 studies
were excluded from the analysis of rs2380205 (one due
to low duplicate concordance, 3 due to low call rate), 2
studies were excluded from the analysis of rs704010
(low call rate) and 13 studies were excluded from the
analysis of rs1292011 (all due to low call rates). As an
additional genotyping quality-control check, we also
evaluated the deviation from Hardy-Weinberg equili-
brium (HWE) for unrelated subjects separately for each
SNP and study. Nine studies had HWE P-values in the
range 0.005 to 0.05 (two studies for rs10995190, two
studies for rs704010, one study for rs10771399, two for
rs1292011 and two for rs865686). Upon examination of
the cluster plots for these studies and SNPs, none
revealed any unusual patterns and these studies were
included in all the analyses. After the above exclusions,
a total of 19,731 unique mutation carriers (12,599
BRCA1 and 7,132 BRCA2) from 40 studies had an
observed genotype for at least 1 of the SNPs and were
included in the primary analysis.
Statistical analysis
The aim of the primary analysis was to evaluate the
association between each genotype and breast cancer
risk within a survival analysis framework. The time vari-
able for each individual was defined to be the time to
breast cancer diagnosis. Each individual was followed
until the first breast cancer diagnosis, ovarian cancer
diagnosis, or bilateral prophylactic mastectomy or the
age at last observation. Only those with a first breast
cancer diagnosis were considered as affected in the
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analysis. Mutation carriers censored at ovarian cancer
diagnosis were considered unaffected. Analysis was con-
ducted by modelling the retrospective likelihood of the
observed genotypes conditional on the disease pheno-
types as previously described [18]. The effect of each
SNP was modelled either as a per-allele hazard ratio
(HR) (multiplicative model) or as separate HRs for het-
erozygotes and homozygotes, and these were estimated
on the logarithmic scale. The HRs were assumed to be
independent of age (that is, we used a Cox propor-
tional-hazards model). The assumption of proportional
hazards was tested by adding a “genotype x age” interac-
tion term to the model in order to fit models in which
the HR changed with age. Analyses were carried out
with the pedigree-analysis software MENDEL [20];
details of this approach have been described previously
[18,21]. We examined between-study heterogeneity by
comparing the models that allowed for study-specific
log-hazard ratios against models in which the same log-
hazard ratio was assumed to apply to all studies.
To investigate whether our results were influenced by
any of our assumptions we performed additional sensi-
tivity analyses. If a SNP is associated with disease survi-
val, the inclusion of prevalent cases may influence the
HR estimates. Current data indicate that five-year survi-
val after a breast cancer diagnosis is over 80% (Cancer
Research - UK, Breast cancer survival statistics) and stu-
dies have suggested no difference in survival between
mutation carriers and non-carriers [22]. We, therefore,
repeated our analysis by excluding mutation carriers
diagnosed more than five years prior to recruitment into
the study. To examine whether SNP associations dif-
fered by type of mutation, we classified BRCA1 muta-
tions according to their potential functional effect
[23-26]. Class 1 mutations were those likely to lead to
the absence of protein expression due to i) reduced
transcript level and/or degradation or instability of trun-
cated proteins, or ii) absence of transcription. Class 1
mutations comprise truncating mutations expected to
trigger nonsense-mediated mRNA decay (NMD) or
translation re-initiation but no production of stable pro-
tein, and deletion of transcription regulatory regions.
Class 2 mutations were those likely to generate stable
mutant proteins with partial or total loss of function
that might also have dominant negative effect. Class 2
mutations include missense substitutions, in-frame dele-
tions and insertions, as well as truncating mutations
with premature stop codons occurring in the last exon.
Mutations whose consequences at transcript or protein
level could not be inferred were not considered for this
classification. These were mainly mutations located in
splice sites but not characterised for their effect at the
transcript level, or large deletions or insertions with
undetermined boundaries.
The associations of these SNPs with ovarian cancer
risk were evaluated within a competing risk analysis fra-
mework [8,9,21], by estimating HRs simultaneously for
breast and ovarian cancers. In this model, each indivi-
dual was at risk of developing either breast or ovarian
cancer, by assuming that the probabilities of developing
each disease were independent conditional on the
underlying genotype. A different censoring process was
used for the competing risk analysis, whereby indivi-
duals were followed up to the age of the first breast or
ovarian cancer diagnosis and were considered to have
developed the corresponding disease. No follow-up was
considered after the first cancer diagnosis. Individuals
were censored for breast cancer at the age of bilateral
prophylactic mastectomy and for ovarian cancer at the
age of bilateral oophorectomy and were assumed to be
unaffected for the corresponding disease. The remaining
individuals were censored at the age at last observation
and were assumed to be unaffected for both diseases.
We further evaluated the associations of these SNPs with
breast cancer subtypes defined by the estrogen receptor
(ER) status of the tumours in BRCA1 and BRCA2 mutation
carriers. The analysis was carried out by an extension of
the retrospective likelihood approach to model the simulta-
neous effect of each SNP on more than one tumour sub-
type [14]. Briefly, this involves modelling the conditional
likelihood of the observed SNP genotypes and tumour sub-
types, given the disease phenotypes. Within this framework
it is possible to estimate simultaneously the HRs for each
tumour subtype and test for heterogeneity in the associa-
tions. Only studies that provided tumour pathology infor-
mation and had genotype information were included in the
analysis. To maximise the available information, genotyped
mutation carriers that were missing information on
tumour characteristics (within each study) were included
in the analysis, and their disease subtype was assumed to
be missing at random [14]. This is a reasonable assumption
given that more than 90% of mutation carriers in our sam-
ple were recruited prior to 2007, when it was uncommon
to use tumour pathology in selecting individuals for
BRCA1 and BRCA2 mutation screening.
To ensure a sufficiently large number of mutation car-
riers within each stratum, we grouped studies from the
same country. All analyses were stratified by country of
residence and used calendar-year- and cohort-specific
cancer incidences for BRCA1 and BRCA2 [27]. For sen-
sitivity analyses, strata with small numbers of mutation
carriers were grouped. We used a robust variance-esti-
mation approach to allow for the non-independence
among related carriers [28].
Results
The analysis included 12,599 BRCA1 and 7,132 BRCA2
mutation carriers who were genotyped successfully for
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at least one of the eight SNPs. Table 1 summarises the
characteristics of the mutation carriers used in the ana-
lysis. In evaluating associations with breast cancer,
10,200 mutation carriers had been diagnosed with a first
breast cancer diagnosis, 1,869 were censored at an ovar-
ian cancer diagnosis, 561 at age of bilateral prophylactic
mastectomy and 7,101 at the age at last observation.
Associations with cancer risk for BRCA1 mutation carriers
Of the eight SNPs, only rs10771399 in PTHLH was
associated with breast cancer risk for BRCA1 mutation
carriers (P-trend = 3 × 10-4, Table 2). The association
was consistent with a multiplicative model in which
each copy of the minor allele was estimated to confer a
HR of 0.87 (95% CI: 0.81 to 0.94). There was no evi-
dence of heterogeneity in the HR estimates across stu-
dies (P-het = 0.24, Additional file 1 Supplementary
Figure 1). There was no evidence that the HRs varied
with age (P = 0.68). The association remained signifi-
cant, with a similar HR estimate (HR = 0.85, 95% CI:
0.77 to 0.93, P-trend = 6 × 10-4, Table 3), when long-
term survivors were excluded from the analysis, suggest-
ing no evidence of survival bias. Interestingly, the asso-
ciation was restricted to BRCA1 carriers of Class 1
mutations (HR = 0.82, 95% CI: 0.74 to 0.90, P-trend = 3
× 10-5, Table 3) with no evidence of association for
Class 2 mutation carriers (HR = 1.00, 0.87 to 1.15, P-
trend = 0.99, P-difference between Class 1 and Class 2
= 0.03).
We found no evidence of association between breast
cancer risk for BRCA1 mutation carriers and any of
the other SNPs under the trend models (P-trend >
0.15). There was, however, some suggestion of an asso-
ciation under the genotype specific model for rs865686
(2df P = 0.06, Table 2), reflecting a lower HR for het-
erozygous carriers than for either homozygote geno-
type. There was marginal evidence of heterogeneity in
the HRs across countries for rs704010 and rs865686
(P-het = 0.04 for both), but examination of the forest
plots revealed that in each case this was mainly due to
a single study/country of relatively small sample size,
with the majority of the HR estimates being close to 1
(Additional file 1 Supplementary Figure 1). There was
no evidence that the HRs varied by age for any of the
SNPs (P > 0.08 for all).
We further evaluated the SNP associations with
breast and ovarian cancer risk simultaneously (Table
4). The associations with breast cancer risk remained
Table 1 Summary characteristics for the 19731 eligible BRCA1 and BRCA2 carriers* used in the analysis
Characteristic BRCA1 BRCA2
Unaffected Breast cancer Unaffected Breast cancer
Number 6,209 6,390 3,322 3,810
Person-years follow-up 264,903 263,068 147,053 168,201
Median age at censure (IQR1) 42 (34 to 50) 40 (34 to 47) 43 (34 to 53) 43 (37 to 50)
Age at censure, N (%)
< 30 1,189 (19.2) 691 (10.8) 611 (18.4) 306 (8.0)
30 to 39 1,161 (26.8) 2,445 (38.3) 834 (25.1) 1,141 (30.0)
40 to 49 1,765 (28.4) 2,191 (34.3) 865 (26.0) 1,394 (36.6)
50 to 59 1,058 (17.0) 812 (12.7) 566 (17.0) 687 (18.0)
60 to 69 380 (6.1) 198 (3.1) 302 (9.1) 226 (5.9)
70+ 156 (2.5) 53 (0.8) 144 (4.3) 56 (1.5)
Year of birth, N (%)
< 1920 28 (0.5) 30 (0.5) 23 (0.7) 44 (1.2)
1920 to 1929 131 (2.1) 196 (3.1) 99 (3.0) 167 (4.4)
1930 to 1939 369 (5.9) 516 (8.1) 232 (7.0) 430 (11.3)
1940 to 1949 832 (13.4) 1,341 (21.0) 458 (13.8) 896 (23.5)
1950 to 1959 1,409 (22.7) 1,989 (31.1) 691 (20.8) 1,160 (30.5)
1960 to 1969 1,703 (27.4) 1,666 (26.1) 902 (27.2) 868 (22.8)
1970+ 1,737 (28.0) 652 (10.2) 917 (27.6) 245 (6.4)
Mutation Class, N (%)
Class 12 4,063 (65.4) 3,878 (60.7) 3,114 (93.7) 3,520 (92.4)
Class 22 1,780 (28.7) 1,973 (30.9) 72 (2.2) 100 (2.6)
Other 366 (5.9) 539 (8.4) 136 (4.1) 190 (5.0)
1 IQR: Interquartile Range
2 See methods for definitions
* Carriers of self-reported white European ancestry only.
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Table 2 SNP genotype distributions and associations with breast cancer risk.
Mutation Genotype Unaffected
N (%)
Affecteda
N (%)
HR 95% CI P-value
CDK2NA/B - rs1011970
BRCA1 GG 4,318 (69.7) 4,460 (70.0) 1
GT 1,698 (27.4) 1,719 (27.0) 1.01 0.94 to 1.09
TT 180 (2.9) 195 (3.1) 1.11 0.91 to 1.35
2-df test 0.61
per allele 1.03 0.96 to 1.09 0.45
BRCA2 GG 2,279 (68.7) 2,586 (67.9) 1
GT 943 (28.4) 1,098 (28.9) 1.08 0.98 to 1.19
TT 94 (2.8) 123 (3.2) 1.23 0.95 to 1.59
2-df test 0.12
per allele 1.09 1.00 to 1.18 0.048
ZNF365 - rs10995190
BRCA1 GG 4,394 (70.9) 4,556 (71.5) 1
GA 1,656 (26.7) 1,662 (26.1) 0.98 0.91 to 1.06
AA 147 (2.4) 156 (2.5) 0.98 0.79 to 1.20
2-df test 0.89
per allele 0.99 0.93 to 1.05 0.64
BRCA2 GG 2,334 (70.4) 2,802 (73.7) 1
GA 913 (27.5) 923 (24.3) 0.86 0.78 to 0.96
AA 68 (20.1) 79 (2.1) 0.96 0.69 to 1.34
2-df test 0.019
per allele 0.90 0.82 to 0.98 0.015
ZMIZ1 - rs704010
BRCA1 CC 2,476 (40.3) 2,504 (39.8) 1
CT 2,814 (45.8) 2,894 (46.0) 1.03 0.96 to 1.10
TT 855 (13.9) 888 (14.1) 1.04 0.93 to 1.15
2-df test 0.69
per allele 1.02 0.97 to 1.07 0.42
BRCA2 CC 1,286 (39.3) 1,443 (38.4) 1
CT 1,496 (45.7) 1,779 (47.3) 1.07 0.97 to 1.18
TT 494 (15.8) 539 (14.3) 0.99 0.86 to 1.14
2-df test 0.32
per allele 1.01 0.95 to 1.08 0.73
10p15 - rs2380205
BRCA1 CC 1,609 (32.5) 1,710 (32.1) 1
CT 2,410 (48.7) 2,625 (49.3) 1.01 0.93 to 1.09
TT 933 (18.8) 990 (18.6) 1.02 0.92 to 1.13
2-df test 0.95
per allele 1.01 0.96 to 1.06 0.75
BRCA2 CC 1,013 (32.8) 1,163 (31.8) 1
CT 1,516 (49.1) 1,816 (49.7) 1.05 0.95 to 1.16
TT 560 (18.1) 681 (18.6) 1.03 0.90 to 1.17
2-df test 0.63
per allele 1.02 0.96 to 1.09 0.57
11q13 - rs614367
BRCA1 CC 4,516 (73.2) 4,581 (72.1) 1
CT 1,511 (24.5) 1,618 (25.5) 1.05 0.98 to 1.14
TT 146 (2.4) 154 (2.4) 1.07 0.87 to 1.32
2-df test 0.34
per allele 1.05 0.98 to 1.12 0.15
BRCA2 CC 2,432 (73.6) 2,723 (71.8) 1
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essentially unchanged in the competing risk analysis,
with only the PTHLH SNP rs10771399 being signifi-
cantly associated with breast cancer risk. There was
some suggestion of a possible association between this
SNP and ovarian cancer risk for BRCA1 mutation car-
riers with risk in the opposite direction (HR for ovar-
ian cancer = 1.14, 95% CI: 1.00 to 1.30, P-trend =
0.06) especially among rare homozygotes (ovarian can-
cer HR for GG = 1.67, 95% CI: 1.05 to 2.64, P-homo-
zygotes = 0.03). This analysis also provided some weak
evidence for an association between SNP rs614367 at
11q13 and ovarian cancer risk for BRCA1 mutation
carriers under the genotype-specific model (2df P-
value = 0.03). There was no evidence that any of the
other SNPs are associated with ovarian cancer risk for
BRCA1 mutation carriers.
Associations with cancer risk for BRCA2 mutation carriers
There was evidence of association with breast cancer
risk for BRCA2 mutation carriers for four SNPs (Table
2). The minor allele of rs10995190 in ZNF365 was asso-
ciated with a reduced risk of breast cancer, where each
copy of allele “A” was estimated to confer a HR of 0.90
(95% CI: 0.82 to 0.98, P-trend = 0.015). There was also
Table 2 SNP genotype distributions and associations with breast cancer risk. (Continued)
CT 799 (24.1) 983 (26.0) 1.06 0.96 to 1.17
TT 76 (2.3) 83 (2.2) 0.97 0.72 to 1.30
2-df test 0.54
per allele 1.03 0.95 to 1.12 0.46
12q24 - rs1292011
BRCA1 AA 1,292 (34.3) 1,331 (35.4) 1
AG 1,825 (48.4) 1,775 (47.3) 0.98 0.89 to 1.07
GG 653 (17.3) 649 (17.3) 1.01 0.90 to 1.14
2-df test 0.80
per allele 1.00 0.94 to 1.06 0.99
BRCA2 AA 824 (35.2) 908 (35.9) 1
AG 1,095 (46.7) 1,225 (48.4) 1.03 0.92 to 1.16
GG 423 (18.1) 397 (15.7) 0.84 0.72 to 0.99
2-df test 0.03
per allele 0.94 0.87 to 1.01 0.10
PTHLH - rs10771399
BRCA1 AA 4,913 (79.4) 5,221 (82.0) 1
AG 1,194 (19.3) 1,082 (17.0) 0.87 0.80 to 0.95
GG 83 (1.3) 65 (1.0) 0.77 0.57 to 1.04
2-df test 1.5 × 10-3
per allele 0.87 0.81 to 0.94 3.2 × 10-4
BRCA2 AA 2,649 (80.0) 3,085 (81.2) 1
AG 620 (18.7) 679 (17.9) 0.95 0.85 to 1.07
GG 45 (1.4) 34 (0.9) 0.74 0.47 to 1.15
2-df test 0.31
per allele 0.93 0.84 to 1.04 0.20
9q31.2 - rs865686
BRCA1 TT 2,521 (40.1) 2,640 (41.4) 1
TG 2,872 (46.4) 2,849 (44.7) 0.95 0.88 to 1.01
GG 799 (12.9) 880 (13.8) 1.05 0.95 to 1.17
2-df test 0.06
per allele 1 0.96 to 1.05 0.85
BRCA2 TT 1,277 (38.6) 1,581 (41.6) 1
TG 1,610 (48.6) 1,717 (45.2) 0.86 0.78 to 0.95
GG 425 (12.8) 501 (13.2) 0.96 0.84 to 1.11
2-df test 7.3 × 10-3
per allele 0.95 0.89 to 1.01 0.10
a Breast Cancer
HR, hazard ratio
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Table 3 Associations with breast cancer risk, after excluding prevalent breast cancer cases, and BRCA1 mutation class.
Unaffected, N Affected, N HR 95% CI P-value
Excluding prevalent breast cancer cases
CDK2NA/B -rs1011970
BRCA1 6,200 3,152 1.05 0.98 to 1.14 0.18
BRCA2 3,319 1,950 1.10 1.00 to 1.22 0.05
ZNF365 - rs10995190
BRCA1 6,201 3,151 0.96 0.89 to 1.04 0.34
BRCA2 3,318 1,949 0.90 0.81 to 1.00 0.05
ZMIZ1 - rs704010
BRCA1 6,149 3,094 1.02 0.96 to 1.08 0.53
BRCA2 3,276 1,919 0.98 0.91 to 1.06 0.64
10p15 - rs2380205
BRCA1 4,955 2,764 1.02 0.95 to 1.08 0.64
BRCA2 3,092 1,884 1.00 0.93 to 1.08 0.92
11q13 - rs614367
BRCA1 6,177 3,144 1.01 0.94 to 1.10 0.73
BRCA2 3,310 1,944 0.99 0.89 to 1.10 0.88
12q24 - rs1292011
BRCA1 3,773 1,798 1.04 0.97 to 1.12 0.29
BRCA2 2,345 1,220 0.96 0.88 to 1.06 0.41
PTHLH - rs10771399
BRCA1 6,194 3,152 0.85 0.77 to 0.93 5.8 × 10-4
BRCA2 3,317 1,944 0.89 0.78 to 1.00 0.06
9q31.2 - rs865686
BRCA1 6,196 3,149 1.01 0.95 to 1.07 0.72
BRCA2 3,315 1,946 0.94 0.87 to 1.02 0.15
BRCA1 analysis by mutation class
CDK2NA/B -rs1011970
Class1 4,040 3,843 1.01 0.94 to 1.10 0.72
Class2 1,771 1,958 1.03 0.91 to 1.16 0.66
ZNF365 - rs10995190
Class1 4,058 3,844 .99 0.92 to 1.07 0.80
Class2 1,774 1,957 0.97 0.86 to 1.09 0.59
ZMIZ1 - rs704010
Class1 3,998 3,787 1.04 0.98 to 1.10 0.22
Class2 1,767 1,936 1.01 0.92 to 1.11 0.85
10p15 - rs2380205
Class1 3,664 3,538 1.01 0.95 to 1.07 0.82
Class2 931 1,263 1.03 0.91 to 1.15 0.67
11q13 - rs614367
Class1 4,024 3,833 1.10 1.02 to 1.19 0.02
Class2 1,764 1,948 0.94 0.84 to 1.06 0.32
12q24 - rs1292011
Class1 2,812 2,521 0.99 0.92 to 1.06 0.71
Class2 642 797 0.97 0.84 to 1.12 0.68
PTHLH - rs10771399
Class1 4,035 3,841 0.82 0.74 to 0.90 3.1 × 10-5
Class2 1,770 1,953 1.00 0.87 to 1.15 0.99
9q31.2 - rs865686
Class1 4,038 3,840 0.98 0.92 to 1.04 0.48
Class2 1,769 1,957 1.03 0.94 to 1.14 0.49
HR, hazard ratio
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Table 4 Competing risk analysis*.
Breast cancer Ovarian cancer
Unaffected
N (%)
Breast
cancer
N (%)
Ovarian
cancer
N (%)
HR 95% CI P-value HR 95% CI P-value
CDK2NA/B - rs1011970
BRCA1 GG 3,328 (69.6) 4,424 (69.9) 1,026 (70.1) 1 1
GT 1,309 (27.4) 1,710 (27.0) 398 (27.2) 1.03 0.95 to 1.11 1.10 0.95 to 1.26
TT 142 (3.0) 194 (3.1) 39 (2.7) 1.09 0.88 to 1.35 0.90 0.61 to 1.32
2-df test 0.57 0.35
per allele 1.04 0.91 to 1.11 0.30 1.04 0.93 to 1.17 0.48
BRCA2 GG 1,972 (68.6) 2578 (67.9) 315 (69.5) 1 1
GT 815 (28.4) 1097 (28.9) 129 (28.5) 1.09 0.98 to 1.21 1.07 0.85 to 1.35
TT 86 (3.0) 122 (3.2) 9 (2.0) 1.19 0.91 to 1.57 0.84 0.40 to 1.77
2-df test 0.15 0.74
per allele 1.09 1.00 to 1.19 0.05 1.03 0.84 to 1.25 0.81
ZNF365 - rs10995190
BRCA1 GG 3,408 (71.3) 4,523 (71.5) 1,019 (69.6) 1 1
GA 1,258 (26.3) 1,650 (26.1) 410 (28.0) 1.00 0.93 to 1.08 1.12 0.98 to 1.28
AA 113 (2.4) 155 (2.5) 35 (2.4) 0.96 0.78 to 1.20 0.90 0.61 to 1.33
2-df test 0.94 0.23
per allele 0.99 0.93 to 1.06 0.88 1.06 0.95 to 1.19 0.32
BRCA2 GG 2,033 (70.4) 2,795 (73.7) 318 (70.2) 1 1
GA 794 (27.7) 920 (24.3) 122 (26.9) 0.86 0.78 to 0.96 0.99 0.78 to 1.25
AA 55 (1.9) 79 (2.1) 13 (2.9) 1.03 0.74 to 1.43 1.58 0.83 to 3.03
2-df test 0.02 0.37
per allele 0.90 0.82 to 0.99 0.03 1.06 0.87 to 1.31 0.55
ZMIZ1 - rs704010
BRCA1 CC 1,904 (40.2) 2,493 (40.0) 583 (40.1) 1 1
CT 2,172 (45.9) 2,871 (46.0) 665 (45.7) 1.02 0.95 to 1.10 1.01 0.89 to 1.15
TT 660 (13.9) 877 (14.1) 206 (14.2) 1.02 0.92 to 1.14 1.01 0.84 to 1.22
2-df test 0.67 0.99
per allele 1.01 0.97 to 1.07 0.58 1.01 0.92 to 1.10 0.90
BRCA2 CC 1,109 (39.0) 1,439 (38.4) 181 (40.1) 1 1
CT 1,306 (46.0) 1,774 (47.3) 192 (43.4) 1.06 0.96 to 1.17 0.96 0.76 to 1.20
TT 426 (15.0) 538 (14.3) 69 (15.6) 1.00 0.86 to 1.15 1.05 0.77 to 1.43
2-df test 0.46 0.81
per allele 1.01 0.95 to 1.08 0.72 1.01 0.87 to 1.18 0.90
10p15 - rs2380205
BRCA1 CC 1,183 (32.2) 1,698 (32.1) 438 (33.2) 1 1
CT 1,796 (48.9) 2,605 (49.3) 634 (48.1) 0.99 0.91 to 1.08 0.91 0.79 to 1.05
TT 696 (18.9) 981 (18.6) 246 (18.7) 1.00 0.90 to 1.12 0.94 0.78 to 1.14
2-df test 0.96 0.45
per allele 1.00 0.95 to 1.06 0.98 0.96 0.87 to 1.06 0.40
BRCA2 CC 872 (32.6) 1,161 (31.8) 143 (33.7) 1 1
CT 1,321 (49.4) 1,812 (49.6) 199 (46.9) 1.04 0.94 to 1.16 0.94 0.74 to 1.19
TT 481 (18.0) 678 (18.6) 82 (19.3) 1.03 0.90 to 1.18 1.01 0.75 to 1.38
2-df test 0.74 0.82
per allele 1.02 0.95 to 1.09 0.61 1.00 0.85 to 1.16 0.98
11q13 - rs614367
BRCA1 CC 3,439 (72.3) 4,547 (72.1) 1,111 (76.2) 1 1
CT 1,212 (25.5) 1,606 (25.5) 311 (21.3) 1.02 0.94 to 1.11 0.83 0.72 to 0.96
TT 109 (2.3) 154 (2.4) 37 (2.5) 1.12 0.91 to 1.39 1.20 0.81 to 1.76
2-df test 0.52 0.03
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some marginal evidence that the minor allele of
rs1011970 near CDKN2A/CDKN2B was associated with
increased breast cancer risk (HR = 1.09, 95% CI: 1.00 to
1.18, P-trend = 0.048). None of the other polymorph-
isms was associated with breast cancer risk for BRCA2
mutation carriers under the multiplicative model. How-
ever, SNPs rs865686 and rs1292011 were associated
with risk under the genotype specific model (2df-P =
0.007 and 0.03 respectively, Table 2). There was some
evidence of heterogeneity in the HRs across countries
for rs1011970 (P-het = 0.005). This appeared to be
mainly due to the USA stratum. The heterogeneity was
no longer significant after removal of that stratum (P-
het = 0.42) and the HR estimate for the association with
breast cancer risk increased to 1.20 (95% CI: 1.09 to
1.32, P-trend = 1 × 10-4). There was no heterogeneity
for any of the other SNPs (P-het > 0.12 for all, Addi-
tional file 1 Supplementary Figure 2). The HR estimates
Table 4 Competing risk analysis*. (Continued)
per allele 1.03 0.91 to 1.10 0.35 0.91 0.80 to 1.03 0.13
BRCA2 CC 2,106 (73.5) 2,716 (71.9) 333 (73.8) 1 1
CT 693 (24.2) 981 (26.0) 108 (24.0) 1.05 0.95 to 1.16 0.95 0.74 to 1.21
TT 66 (2.3) 83 (2.2) 10 (2.2) 0.96 0.71 to 1.28 0.87 0.46 to 1.63
2-df test 0.62 0.84
per allele 1.03 0.94 to 1.12 0.56 0.94 0.77 to 1.15 0.56
12q24 - rs1292011
BRCA1 AA 997 (34.1) 1,321 (35.4) 305 (34.9) 1 1
AG 1,406 (48.2) 1,765 (47.3) 429 (49.1) 1.00 0.90 to 1.10 1.11 0.93 to 1.31
GG 517 (17.7) 645 (17.3) 140 (16.0) 1.01 0.89 to 1.15 0.98 0.78 to 1.24
2-df test 0.97 0.39
per allele 1.00 0.94 to 1.07 0.91 1.01 0.91 to 1.13 0.82
BRCA2 AA 715 (35.0) 907 (35.9) 110 (36.5) 1 1
AG 961 (47.0) 1222 (48.4) 137 (45.5) 1.02 0.90 to 1.15 0.94 0.71 to 1.25
GG 370 (18.1) 396 (15.7) 54 (17.9) 0.83 0.70 to 0.97 0.89 0.61 to 1.28
2-df test 0.03 0.80
per allele 0.93 0.86 to 1.00 0.07 0.94 0.78 to 1.13 0.51
PTHLH - rs10771399
BRCA1 AA 3,810 (79.8) 5,179 (81.9) 1,145 (78.4) 1 1
AG 909 (19.0) 1078 (17.1) 289 (19.8) 0.89 0.81 to 0.97 1.09 0.93 to 1.26
GG 56 (1.2) 65 (1.0) 27 (1.9) 0.86 0.63 to 1.16 1.67 1.05 to 2.64
2-df test 0.02 0.06
per allele 0.90 0.83 to 0.97 6.4 × 10-3 1.14 1.00 to 1.30 0.06
BRCA2 AA 2,289 (79.7) 3,076 (81.2) 369 (81.5) 1 1
AG 545 (19.0) 678 (17.9) 76 (16.8) 0.94 0.84 to 1.06 0.88 0.67 to 1.16
GG 37 (1.3) 34 (0.9) 8 (1.8) 0.79 0.49 to 1.26 1.48 0.63 to 3.46
2-df test 0.38 0.43
per allele 0.93 0.84 to 1.04 0.19 0.96 0.75 to 1.23 0.75
9q31.2 - rs865686
BRCA1 TT 1,935 (40.5) 2,621 (41.5) 605 (41.3) 1 1
TG 2,206 (46.2) 2,825 (44.7) 690 (47.1) 0.94 0.88 to 1.01 0.99 0.87 to 1.12
GG 633 (13.3) 877 (13.9) 169 (11.5) 1.03 0.93 to 1.15 0.85 0.70 to 1.03
2-df test 0.12 0.23
per allele 1.00 0.95 to 1.05 0.88 0.94 0.86 to 1.03 0.17
BRCA2 TT 1,103 (38.4) 1,576 (41.6) 179 (39.6) 1 1
TG 1400 (48.8) 1712 (45.2) 215 (47.6) 0.85 0.77 to 0.94 0.91 0.73 to 1.14
GG 367 (12.8) 501 (13.2) 58 (12.8) 0.97 0.84 to 1.12 0.98 0.71 to 1.35
2-df test 4.6 × 10-3 0.70
per allele 0.94 0.88 to 1.01 0.10 0.97 0.83 to 1.13 0.67
Associations with breast and ovarian cancer risk for BRCA1 and BRCA2 carriers.
*Censoring process described in the methods
HR, hazard ratio
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for the four associated SNPs were similar when long-
term survivors were excluded from the analysis (Table
3). Consistent with the results of the main analysis,
rs10995190 in ZNF365 and rs1011970 near CDKN2A/
CDKN2B provided marginal evidence of association
using the trend-test statistic (P-trend = 0.05 for both)
and SNPs rs865686 was associated with breast cancer
risk under the genotype specific model (2df-P = 0.03).
SNP rs1292011 was not associated with breast cancer
risk in this analysis. A somewhat smaller HR estimate
was obtained for the PTHLH SNP rs10771399 compared
to the main analysis (per-allele HR = 0.89, 95% CI: 0.78
to 1.00, P-trend = 0.06). The attenuation of the associa-
tion in the overall analysis could have occurred if the
SNP is also associated with prognosis. However, the dif-
ference in the HRs was small. The results for the
remaining SNPs were similar and non-significant. None
of SNPs were associated with ovarian cancer risk for
BRCA2 mutation carriers (Table 4).
Associations by tumour ER-status
Table 5 summarises the associations of the eight SNPs
with breast cancer ER status in BRCA1 and BRCA2
mutation carriers. Only the PTHLH SNP rs10771399 was
associated with ER-negative breast cancer for BRCA1
mutation carriers (ER-negative HR = 0.81, 95% CI: 0.74
to 0.90, P-trend = 3.8 × 10-5). There was also marginal
evidence that SNP rs704010 near ZMIZ1 was associated
with ER-positive breast cancer for BRCA1 mutation car-
riers (ER-positive HR = 1.12, 95% CI: 1.00 to 1.26, P-
trend = 0.046). However, the associations between ER-
negative and ER-positive breast cancer among BRCA1
mutation carriers were only significantly different for
SNP rs1292011 at 12q24 (P-heterogeneity = 0.045).
Despite the small number of BRCA2 ER-negative
breast cancers, there was a suggestion that the minor
allele of the PTHLH SNP rs10771399 is protective for
ER-negative breast cancer for BRCA2 mutation carriers
(HR for ER-negative = 0.78, 95% CI: 0.62 to 1.00, P-
Table 5 Associations with estrogen receptor-positive and estrogen receptor-negative breast cancer risk for BRCA1 and
BRCA2 carriers.
ER-positive ER-negative
Unaffected
N
ER-positive N ER-negative N ER status unknown N HR 95% CI P-
value
HR 95% CI P-value P-dif
CDK2NA/B -
rs1011970
BRCA1 4,893 559 1,888 2,841 0.95 0.81 to 1.12 0.56 1.03 0.95 to 1.11 0.47 0.41
BRCA2 2,928 1,372 424 1,649 1.10 1.00 to 1.22 0.05 1.15 0.96 to 1.37 0.12 0.70
ZNF365 -
rs10995190
BRCA1 4,895 559 1,887 2,843 0.88 0.74 to 1.04 0.14 1.01 0.94 to 1.10 0.75 0.16
BRCA2 2,927 1,370 406 1,648 0.89 0.80 to 1.00 0.043 0.87 0.71 to 1.07 0.19 0.84
ZMIZ1 - rs704010
BRCA1 4,842 548 1,846 2,811 1.12 1.00 to 1.26 0.046 1.00 0.94 to 1.06 0.91 0.08
BRCA2 2,887 1,347 401 1,636 1.01 0.93 to 1.09 0.91 1.00 0.87 to 1.14 0.95 0.91
10p15 -
rs2380205
BRCA1 4,465 540 1,812 2,513 0.90 0.80 to 1.01 0.08 1.02 0.96 to 1.09 0.46 0.06
BRCA2 2,701 1,341 396 1,543 1.02 0.95 to 1.10 0.60 0.94 0.82 to 1.08 0.39 0.31
11q13 - rs614367
BRCA1 4,879 557 1,886 2,832 1.09 0.93 to 1.29 0.30 1.04 0.96 to 1.12 0.40 0.59
BRCA2 2,921 1,365 405 1,639 1.06 0.96 to 1.17 0.26 0.84 0.69 to 1.04 0.10 0.05
12q24 -
rs1292011
BRCA1 3,429 308 1,043 2,031 0.87 0.74 to 1.02 0.09 1.05 0.98 to 1.13 0.12 0.046
BRCA2 2,065 813 239 1,170 0.95 0.86 to 1.04 0.28 0.98 0.82 to 1.16 0.78 0.79
PTHLH -
rs10771399
BRCA1 4,889 557 1,887 2,842 0.94 0.78 to 1.13 0.52 0.81 0.74 to 0.90 3.8 × 10-5 0.20
BRCA2 2,926 1,366 406 1,648 0.97 0.86 to 1.10 0.68 0.78 0.62 to 1.00 0.049 0.12
9q31.2 - rs865686
BRCA1 4,892 559 1,888 2,836 0.92 0.81 to 1.03 0.15 1.01 0.95 to 1.08 0.68 0.16
BRCA2 2,924 1,370 405 1,645 0.91 0.84 to 0.99 0.028 1.07 0.92 to 1.25 0.40 0.08
ER, estrogen receptor; HR, hazard ratio
Antoniou et al. Breast Cancer Research 2012, 14:R33
http://breast-cancer-research.com/content/14/1/R33
Page 11 of 18
trend = 0.049), but there was no association with ER-
positive breast cancer. There was evidence that SNPs
rs10995190 near ZNF365, rs865686 at 9q31.2 and
rs1011970 near CDKN2A/B are associated with ER-posi-
tive breast cancer for BRCA2 mutation carriers (P-trend
= 0.043, 0.028 and 0.05 respectively). However, the HR
estimates were not significantly different from those for
ER-negative breast cancer.
Discussion
We have investigated eight novel breast cancer suscept-
ibility loci identified through breast cancer GWAS
[15-17] for their associations with breast cancer risk for
BRCA1 and BRCA2 mutation carriers using data from
the CIMBA. The estimated per-allele ORs associated
with the minor allele of each SNP from the population-
based studies varied from 0.85 to 1.15, and only four of
the eight SNPs had ORs of less than 0.90 or greater
than 1.10 (rs10995190, rs614367, rs865686 and
rs10771399) [15-17]. For BRCA1 mutation carriers, only
SNP rs10771399 at 12p11 was associated with the over-
all risk of breast cancer, whereas SNPs rs10995190 at
10q21, rs1011970 at 9p21, rs865686 at 9q31.2 and
rs1292011 at 12q24 were associated with breast cancer
risk for BRCA2 mutation carriers. The magnitude of the
estimated HRs for all these SNPs were consistent with
the OR estimates for the risk of breast cancer in the
general population. The power to detect associations
with SNPs conferring relative risks in the range of 0.90
to 1.10 was limited by our sample size, particularly
among BRCA2 mutation carriers [29].
Based on the HR estimates and associated 95% confi-
dence intervals, given our sample size of BRCA1 muta-
tion carriers, it is unlikely that the relative risks for
overall BRCA1 breast cancer risk are of similar magni-
tude to those estimated in the general population for
SNPs rs10995190 at 10q21 (estimated odds ratio (OR)
from the replication stage of the GWAS = 0.76),
rs2380205 at 10p15 (OR = 0.94), rs614367 at 11q13 (OR
= 1.15), rs1292011 at 12q24 (OR = 0.92) and rs865686
at 9q31.2 (OR = 0.89), since the 95% confidence inter-
vals for the HRs do not include the estimated OR from
the population-based studies. Similarly, the HRs for
BRCA2 breast cancer risk exclude the ORs from the
general population for SNPs rs2380205 at 10p15 and
rs614367 at 11q13. Taken together, these findings sug-
gest that SNPs rs2380205 at 10p15 and rs614367 at
11q13 do not modify breast cancer risk in either BRCA1
or BRCA2 mutation carriers. A replication study by
BCAC, involving close to 50,000 breast cancer cases and
50,000 controls, found only weak evidence for associa-
tion of rs2380205 at 10p15 with breast cancer risk in
the general population [Lambrechts and Easton personal
communication, manuscript submitted] suggesting that
the original finding (OR = 0.94, P = 5 × 10-7 [15]) may
have been a false positive. If this were true, the absence
of an association in carriers would be expected. The
lack of evidence for an association with the 11q13 SNP
rs614367 with BRCA1 and BRCA2 breast cancer risk is
more surprising since the association in the general
population is relatively strong and consistently replicated
(OR 1.21, 95% CI 1.17 to 1.25 in the recent BCAC ana-
lysis [Lambrechts and Easton personal communication,
manuscript submitted]). The association in the general
population appears to be restricted to ER-positive dis-
ease, which would explain the lack of association for
BRCA1 carriers but not BRCA2 carriers. This is perhaps
the clearest evidence so far of a departure from a multi-
plicative interaction between a common susceptibility
locus and a BRCA2 mutation on the risk of developing
breast cancer. The lack of an association in BRCA1 car-
riers for rs1292011 and rs865686 is also consistent with
the observation that these associations are stronger for
ER-positive disease in the general population [16]. The
absence of an association for ZNF365 rs10995190 in
BRCA1 carriers is more surprising since this association
appears to be unrelated to ER status in the general
population [Lambrechts and Easton personal communi-
cation, manuscript submitted] [30].
Of the eight SNPs investigated, the strongest associa-
tion was found between SNP rs10771399 at 12p11 and
breast cancer risk for BRCA1 mutation carriers. Other
loci previously found to be associated with BRCA1
breast cancer risk include the 19p13 and 6q25.1 loci
[6,9], TOX3 and CASP8 [3,5,7]. Analysis by tumour ER-
status revealed that rs10771399 at 12p11 has a stronger
association with ER-negative than ER-positive breast
cancer for both BRCA1 and BRCA2 mutation carriers.
The ER-specific HRs were similar for both genes, sug-
gesting that this SNP is primarily associated with ER-
negative breast cancer, although results from the general
population suggested similar ORs for ER-positive and
ER-negative breast cancer (0.87 for ER-positive disease,
0.85 for ER-negative disease [16]). Interestingly, the
association among BRCA1 mutation carriers was
restricted to those carrying mutations proven or pre-
dicted to lead to absence of protein expression (Class 1)
with no evidence for an association in carriers of
BRCA1 mutations likely to generate stable mutant pro-
teins (Class 2) (P-diff = 0.03). This observation suggests
that the modifying effect of SNP rs10771399 at 12p11
might be attenuated for tumours that retain residual
BRCA1 function or that retain the capacity to bind to
some of its partners. rs10771399 lies in a region at
12p11 that contains PTHLH (parathyroid hormone-like
hormone isoform 1, also known as PTHRP - parathyroid
hormone-related protein) and CCDC91. PTHLH is a
plausible candidate cancer susceptibility gene. It encodes
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a protein that regulates endochondral bone development
and epithelial-mesenchymal interactions during the for-
mation of the mammary glands. The receptor of this
hormone, PTHR1, is responsible for most cases of
humoral hypercalcemia of malignancy [31]. It is pro-
duced by various types of carcinomas [32], and is an
important factor in the development of bone metastasis
[33].
We found that SNP rs10995190 ZNF365 is associated
with BRCA2 breast cancer risk. A different SNP
(rs16917302) in ZNF365, which is only weakly corre-
lated with rs10995190 (pairwise r2 is approximately 0.10
in the present sample) was previously identified via a
GWAS of breast cancer in BRCA2 mutation carriers
[10]. These results suggest that there could be a causal
associated variant correlated with both rs10995190 and
rs16917302, or alternatively more than one causal dis-
ease variant in this locus. SNP rs10995190 has also
recently been found to be associated with mammo-
graphic density in the general population [34]. Previous
studies found that mammographic density modifies
breast cancer risk for BRCA2 mutation carriers [35],
raising the possibility that this locus modifies breast
cancer risk for BRCA2 mutation carriers through its
influence on mammographic density. However, mam-
mographic density has also been shown to modify the
breast cancer risk for BRCA1 carriers, which also makes
the absence of association for rs10995190 in BRCA1 car-
riers somewhat surprising. Mammographic density data
are not available in the CIMBA sample to test this
hypothesis explicitly.
There was no evidence of association with ovarian
cancer risk for BRCA1 or BRCA2 mutation carriers for
any of the SNPs, with the exception of some weak evi-
dence for SNPs rs10771399 and rs614367 for BRCA1
carriers. This is not surprising, since all SNPs were
selected on the basis of prior evidence of association
with breast cancer risk in the general population and
none of these SNPs have so far been found to be asso-
ciated with ovarian cancer in general population
through the ongoing GWAS [36-38].
Conclusions
The per-allele HRs estimated for each of the associated
loci in the present report are modest, and in isolation
would have only a small impact on the absolute risks of
developing breast cancer. However, we have shown pre-
viously that modifier SNPs in combination can result in
large differences in the absolute risk of developing
breast cancer for carriers at the extreme percentiles of
the combined SNP distribution [5,39]. Furthermore, the
causal variants underlying these loci may confer larger
relative risks. Considering all reported modifying loci by
the CIMBA consortium, there are now six loci in total
that are associated with breast cancer risk for BRCA1
mutation carriers (19p13, 6q25.1, 12p11, TOX3, 2q35
and CASP8) and 13 loci which are known to be asso-
ciated with BRCA2 breast cancer risk (FGFR2, TOX3,
MAP3K1, LSP1, 2q35, SLC4A7, 5p12, 1p11.2, ZNF365,
CDKN2A/B, 9q31.2, 12q24 and RAD51). Ongoing
GWAS in BRCA1 and BRCA2 mutation carriers and in
the general population are likely to identify further
modifier loci and taken together, they may lead to more
accurate risk predictions in mutation carriers with
implications for clinical management, and to a better
understanding of the biology of tumour development in
mutation carriers.
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